Study of proteomics in blood of women with breast cancer

Not yet recruiting

• Conditions: Malignant neoplasm of overlappingsites of breast,

• Registration Number: CTRI/2021/09/036703
• Lead Sponsor: All India Institute of Medical Sciences New Delhi

Brief Summary

Breast cancer is the most frequent cancer among women in the world with an estimated 2.08 million new cancer cases diagnosed in 2018, which is much higher than the 1.67 million new cases diagnosed in 2012, constituting about 25% of all cancers. The available Indian literature and our clinical experience suggest that the age at presentation, risk factors, outcome and behavior of most of our breast cancer patients differ from those reported in the west. There is paucity of published literature on the risk factors and biomarkers for breast cancers in the Indian setting. The available literature focusses on the clinical and epidemiological factors study. An understanding of the underlying biological mechanisms of carcinogenesis and the altered molecular events in breast cancer can be studied with help of differential proteomics. Genes work at the protein level, and comparisons of transcript and corresponding protein expression have shown that mRNA and protein levels are not necessarily highly correlative. Since almost all therapeutic intervention strategies involve targeting and modulating protein function and activity, it is imperative that proteomics forms a central analyses of mechanism underlying tumorigenesis in breast cancer. Keeping the differences in disease presentation and aggressive behaviour in Indian women, we wish to study the differential proteomics in our patients. The collaborative work in studying the proteomics in liquid biopsy in breast cancer patients may help us to plan further studies which may give an insight into the etiological differences. Furthermore, differentially expressed protein pathways in such women may help identify potential therapeutic targets.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-10
• Last Update Posted: 2021-10-09

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Treatment naïve biopsy proven breast cancer women Patients giving consent to participate in the study.

Exclusion Criteria

pregnant and lactating women.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
study of Differential proteomics in treatment naïve breast cancer women	Baseline

Secondary Outcome Measures

Name	Time	Method
Differential proteomics after Neo-adjuvant chemotherapy in patients receiving the same	10-14 weeks from baseline

Trial Locations

Locations (1)

All India Institute of Medical Sciences New Delhi; 🇮🇳 South, DELHI, India

All India Institute of Medical Sciences New Delhi

🇮🇳South, DELHI, India

Dr Suhani

Principal investigator

01126594560

drsuhani@gmail.com